Updated overall survival after abiraterone acetate in mCRPC

According to a new article, to be published on line today in The Lancet, abiraterone acetate + prednisone provides a median overall survival benefit of 4.6 months compared to a placebo in men with metastatic, castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel-based chemotherapy. … READ MORE …